Standard

Experimental comparison of the in vivo efficacy of two novel anticancer therapies. / Ruzanova, Vera S.; Proskurina, Anastasia S.; Ritter, Genrikh S. et al.

In: Anticancer research, Vol. 41, No. 7, 07.2021, p. 3371-3387.

Research output: Contribution to journal › Article › peer-review

Harvard

Ruzanova, VS, Proskurina, AS, Ritter, GS, Efremov, YR, Nikolin, VP, Popova, NA, Naprimerov, VA, Dolgova, EV, Potter, EA, Kirikovich, SS, Levites, EV, Mustafin, ZS, Lashin, SA, Burakova, EA, Stetsenko, DA, Ostanin, AA, Chernykh, ER & Bogachev, SS 2021, 'Experimental comparison of the in vivo efficacy of two novel anticancer therapies', Anticancer research, vol. 41, no. 7, pp. 3371-3387. https://doi.org/10.21873/anticanres.15125

APA

Ruzanova, V. S., Proskurina, A. S., Ritter, G. S., Efremov, Y. R., Nikolin, V. P., Popova, N. A., Naprimerov, V. A., Dolgova, E. V., Potter, E. A., Kirikovich, S. S., Levites, E. V., Mustafin, Z. S., Lashin, S. A., Burakova, E. A., Stetsenko, D. A., Ostanin, A. A., Chernykh, E. R., & Bogachev, S. S. (2021). Experimental comparison of the in vivo efficacy of two novel anticancer therapies. Anticancer research, 41(7), 3371-3387. https://doi.org/10.21873/anticanres.15125

Vancouver

Ruzanova VS, Proskurina AS, Ritter GS, Efremov YR, Nikolin VP, Popova NA et al. Experimental comparison of the in vivo efficacy of two novel anticancer therapies. Anticancer research. 2021 Jul;41(7):3371-3387. doi: 10.21873/anticanres.15125

Author

Ruzanova, Vera S. ; Proskurina, Anastasia S. ; Ritter, Genrikh S. et al. / Experimental comparison of the in vivo efficacy of two novel anticancer therapies. In: Anticancer research. 2021 ; Vol. 41, No. 7. pp. 3371-3387.

BibTeX

@article{45cd9b2f082648e8aff493081ca5db74,
title = "Experimental comparison of the in vivo efficacy of two novel anticancer therapies",
abstract = "Background/Aim: We compared the therapeutic efficacy of two recently developed experimental anticancer technologies: 1) in situ vaccination based on local immunotherapy with CpG oligonucleotides and anti-OX40 antibodies to activate antitumor immune response and 2) {"}Karanahan{"} technology [from the Sanskrit kāraa ('source') + han ('to kill')] based on the combined injection of cyclophosphamide and double-stranded DNA to eradicate cancer stem cells. Materials and Methods: The anticancer approaches were compared on three types of mouse malignant tumors with different grades of immunogenicity: weakly immunogenic carcinoma Krebs-2, moderately immunogenic Lewis carcinoma, and highly immunogenic A20 B-cellular lymphoma. Results: Our results indicated that in situ vaccination was the most effective against the highly immunogenic tumor A20. In addition, {"}Karanahan{"} demonstrated high efficiency in all types of tumors, regardless of their immunogenicity or size. Conclusion: {"}Karanahan{"} therapy showed higher efficacy relative to in situ vaccination with CpG oligonucleotides and anti-OX40 antibodies.",
keywords = "Anti-OX40 antibody, CpG oligonucleotides, Cyclophosphamide, Double-stranded DNA, Karanahan technology, Antigens, Neoplasm/immunology, Immunotherapy/methods, Male, Oligodeoxyribonucleotides/immunology, Cyclophosphamide/immunology, Antibodies/immunology, DNA/immunology, Lymphoma/immunology, Mice, Inbred CBA, Female, Carcinoma, Lewis Lung/immunology, Receptors, OX40/immunology, Mice, Inbred C57BL, Antigens, Differentiation/immunology, Antineoplastic Agents/immunology, Vaccination/methods, Neoplastic Stem Cells/immunology, Animals, Cell Line, Tumor, Mice, Mice, Inbred BALB C",
author = "Ruzanova, {Vera S.} and Proskurina, {Anastasia S.} and Ritter, {Genrikh S.} and Efremov, {Yaroslav R.} and Nikolin, {Valeriy P.} and Popova, {Nelly A.} and Naprimerov, {Vasiliy A.} and Dolgova, {Evgenia V.} and Potter, {Ekaterina A.} and Kirikovich, {Svetlana S.} and Levites, {Evgeniy V.} and Mustafin, {Zakhar S.} and Lashin, {Sergey A.} and Burakova, {Ekaterina A.} and Stetsenko, {Dmitry A.} and Ostanin, {Alexandr A.} and Chernykh, {Elena R.} and Bogachev, {Sergey S.}",
note = "Funding Information: The work was supported by the Russian Ministry of Science and High Education via the Institute of Cytology and Genetics (state budget project No 0259-2021-0013) and Russian Foundation for Basic Research (grant No 18-29-09045). Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jul,
doi = "10.21873/anticanres.15125",
language = "English",
volume = "41",
pages = "3371--3387",
journal = "Anticancer research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

RIS

TY - JOUR

T1 - Experimental comparison of the in vivo efficacy of two novel anticancer therapies

AU - Ruzanova, Vera S.

AU - Proskurina, Anastasia S.

AU - Ritter, Genrikh S.

AU - Efremov, Yaroslav R.

AU - Nikolin, Valeriy P.

AU - Popova, Nelly A.

AU - Naprimerov, Vasiliy A.

AU - Dolgova, Evgenia V.

AU - Potter, Ekaterina A.

AU - Kirikovich, Svetlana S.

AU - Levites, Evgeniy V.

AU - Mustafin, Zakhar S.

AU - Lashin, Sergey A.

AU - Burakova, Ekaterina A.

AU - Stetsenko, Dmitry A.

AU - Ostanin, Alexandr A.

AU - Chernykh, Elena R.

AU - Bogachev, Sergey S.

N1 - Funding Information: The work was supported by the Russian Ministry of Science and High Education via the Institute of Cytology and Genetics (state budget project No 0259-2021-0013) and Russian Foundation for Basic Research (grant No 18-29-09045). Publisher Copyright: © 2021 International Institute of Anticancer Research. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/7

Y1 - 2021/7

N2 - Background/Aim: We compared the therapeutic efficacy of two recently developed experimental anticancer technologies: 1) in situ vaccination based on local immunotherapy with CpG oligonucleotides and anti-OX40 antibodies to activate antitumor immune response and 2) "Karanahan" technology [from the Sanskrit kāraa ('source') + han ('to kill')] based on the combined injection of cyclophosphamide and double-stranded DNA to eradicate cancer stem cells. Materials and Methods: The anticancer approaches were compared on three types of mouse malignant tumors with different grades of immunogenicity: weakly immunogenic carcinoma Krebs-2, moderately immunogenic Lewis carcinoma, and highly immunogenic A20 B-cellular lymphoma. Results: Our results indicated that in situ vaccination was the most effective against the highly immunogenic tumor A20. In addition, "Karanahan" demonstrated high efficiency in all types of tumors, regardless of their immunogenicity or size. Conclusion: "Karanahan" therapy showed higher efficacy relative to in situ vaccination with CpG oligonucleotides and anti-OX40 antibodies.

AB - Background/Aim: We compared the therapeutic efficacy of two recently developed experimental anticancer technologies: 1) in situ vaccination based on local immunotherapy with CpG oligonucleotides and anti-OX40 antibodies to activate antitumor immune response and 2) "Karanahan" technology [from the Sanskrit kāraa ('source') + han ('to kill')] based on the combined injection of cyclophosphamide and double-stranded DNA to eradicate cancer stem cells. Materials and Methods: The anticancer approaches were compared on three types of mouse malignant tumors with different grades of immunogenicity: weakly immunogenic carcinoma Krebs-2, moderately immunogenic Lewis carcinoma, and highly immunogenic A20 B-cellular lymphoma. Results: Our results indicated that in situ vaccination was the most effective against the highly immunogenic tumor A20. In addition, "Karanahan" demonstrated high efficiency in all types of tumors, regardless of their immunogenicity or size. Conclusion: "Karanahan" therapy showed higher efficacy relative to in situ vaccination with CpG oligonucleotides and anti-OX40 antibodies.

KW - Anti-OX40 antibody

KW - CpG oligonucleotides

KW - Cyclophosphamide

KW - Double-stranded DNA

KW - Karanahan technology

KW - Antigens, Neoplasm/immunology

KW - Immunotherapy/methods

KW - Male

KW - Oligodeoxyribonucleotides/immunology

KW - Cyclophosphamide/immunology

KW - Antibodies/immunology

KW - DNA/immunology

KW - Lymphoma/immunology

KW - Mice, Inbred CBA

KW - Female

KW - Carcinoma, Lewis Lung/immunology

KW - Receptors, OX40/immunology

KW - Mice, Inbred C57BL

KW - Antigens, Differentiation/immunology

KW - Antineoplastic Agents/immunology

KW - Vaccination/methods

KW - Neoplastic Stem Cells/immunology

KW - Animals

KW - Cell Line, Tumor

KW - Mice

KW - Mice, Inbred BALB C

UR - http://www.scopus.com/inward/record.url?scp=85109345711&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15125

DO - 10.21873/anticanres.15125

M3 - Article

C2 - 34230133

AN - SCOPUS:85109345711

VL - 41

SP - 3371

EP - 3387

JO - Anticancer research

JF - Anticancer research

SN - 0250-7005

IS - 7

ER -

ID: 29082135